Translate the text from Welsh to English.



 
Mae MicroPharm Ltd yn datblygu cynnyrch imiwnotherapi i drin clefydau heintus a chyflyrau tocsig aciwt ac mae ganddo ddau wrthwenwyn ar y gweill ar gyfer trin brathiadau gan y wiber garped o Orllewin Affrica a'r wiber gyffredin.   
  
Bydd y prosiect ehangu'n costio £2m, gyda Llywodraeth Cymru'n cyfrannu £150k at hwnnw ac yn golygu agor cyfleuster newydd yng Nghilgerran a chadw ei brif safle yng Nghastell Newydd Emlyn. Disgwylir i'r buddsoddiad hwn greu 15 o swyddi a diogelu 14 swydd arall, gan ddod â'r cyfanswm a gyflogir gan y cwmni i 51 .   
  
Golyga y bydd MicroPharm felly, fel Protherics UK Ltd, sef cwmni yn Llandysul sy'n rhan o grŵp BTG International,  yn gyflenwr blaengar ym maes gwrthwenwynau o fewn Ewrop, Affrica ac UDA.   
  
Mae'r clwstwr unigryw hwn o gwmnïau yn y Gorllewin yn cynnwys Ig\-Innovations Ltd, hefyd yn Llandysul, yn cynhyrchu gwrthgyrff ar gyfer y sector ymchwil, diagnostig, biodechnegol a fferyllol, gan gynnwys MicroPharm, ac ar gyfer eu gwerthu'n uniongyrchol.   
  
Meddai Ysgrifennydd yr Economi, Ken Skates: 
> "Mae'n dipyn o gamp bod yr ardal fach hon o gefn gwlad y Gorllewin wedi dod yn arweinydd byd mewn maes hynod arbenigol, cystadleuol ac uchel iawn ei werth. Mae'n dangos unwaith eto yr ystod o arbenigeddau sydd gennym yng Nghymru yn y sector gwyddorau bywyd.


> "Mae MicroPharm yn rhan allweddol o'n harbenigedd  fel gwlad ac rwy'n falch iawn y bydd help gan Lywodraeth Cymru yn galluogi'r cwmni i fwrw ymlaen â'i gynlluniau i ehangu ar unwaith. Bydd y cwmni'n defnyddio'r buddsoddiad hwn i ddarparu'r cyfleusterau ychwanegol sydd eu hangen iddo allu cwrdd â'r cynnydd yn y galw am ei gynnyrch trwy'r byd. Bydd y cwmni'n gallu cynyddu ei ystod o gynhyrchion a datblygu'i waith ymchwil i driniaethau ar gyfer clefydau difaol fel  Clostridium difficile (CDI) ac Ebola.


> "Bydd y prosiect ehangu pwysig hwn yn dyfnhau gwreiddiau'r cwmni ymchwil fferyllol a gweithgynhyrchu arbenigol hwn yn y Gorllewin ac yn creu swyddi o'r ansawdd uchaf ar gyfer pobl leol."

Ychwanegodd y Gweinidog Sgiliau  a Gwyddoniaeth, Julie James: 
> "Mae sector gwyddorau bywyd Cymru wedi mynd o nerth i nerth dros y blynyddoedd diwethaf a bydd y cyhoeddiad diweddaraf hwn yn newyddion da i'r gymuned leol, economi ehangach Cymru a'r farchnad fferyllol fyd\-eang.


> "Fel gwlad gymharol fach, mae Cymru'n gwneud rhyfeddodau o ran datblygiadau gwyddonol ac ymchwil o safon byd ac mae'r Llywodraeth hon wedi ymrwymo i helpu cwmnïau arloesol fel MicroPharm i sicrhau bod y sector aruthrol bwysig hwn yn parhau i dyfu yng Nghymru."

Dywedodd Pennaeth MicroPharm, Ian Cameron:   

> "Mae'r safle yng Nghastell Newydd Emlyn bellach yn rhy fach i ni a bydd y cyfleuster gweithgynhyrchu newydd yng Nghilgerran yn sylfaen y gall y cwmni dyfu arno at y dyfodol. Mae Llywodraeth Cymru  wedi helpu MicroPharm i dyfu ers ei ddechrau ac rydyn ni'n ddiolchgar iddi am barhau i'n helpu".

Arbenigedd MicroPharm yw ei ystod o gynnyrch imiwnotherapi clinigol \- ar gyfer trin argyfyngau aciwt sy'n bygwth bywyd ac sydd eu hangen ar frys naill ai am nad oes triniaeth arall yn bod neu am fod triniaethau eraill yn beryglus neu'n aneffeithiol.   
Yn ogystal â datblygu gwrthwenwynau, mae MicroPharm yn gweithio hefyd ar wrthdocsin risin, hynny yn sgil ennill contract gwerth hyd at £7m gan y Labordy Gwyddoniaeth a Thechnoleg Amddiffyn (Dstl) ar ran y Weinyddiaeth Amddiffyn (MOS). Mae'n golygu cynhyrchu gwrthgyrff defaid i risin a'u prosesu  i gynhyrchu cynnyrch sy'n addas i'w defnyddio gan bobl. Mae risin yn wenwyn angheuol a does dim gwrthwenwyn yn bod ar ei gyfer.   
  
Mae gan MicroPharm nifer o gynnyrch imiwnotherapi newydd ar y gweill, i drin pobl ac anifeiliaid, rai ohonyn nhw ond yn dechrau cael eu datblygu ac eraill eisoes wedi cyrraedd cam y treialon clinigol ac a ddaw ar y farchnad rhwng 2018\-2021\.   






Translation:


 
MicroPharm Ltd develops immunotherapy products to target infectious diseases and acute toxic conditions and currently produce two anti\-venoms for the treatment of snakebites from the European common adder and the carpet viper in West Africa.  
  
Its planned £2m expansion, supported by £150K from the Welsh Government, will see it open new facilities at Cilgerran while retaining its base in Newcastle Emlyn. The investment is expected to create 15 jobs and safeguard a further 14, bringing the total headcount to 51\.  
  
It means that MicroPharm will become a leading supplier of high quality anti\-venoms to Europe and Africa, like Protherics UK Ltd, a BTG International group company based in Llandysul, who provide antivenin for North American pit viper envenomation in the USA.  
  
The unique West Wales cluster includes Ig\-Innovations Ltd, also based near Llandysul, which produces antibodies for supply to the research, diagnostic, biotech and pharmaceutical sector including MicroPharm, as well as direct sales.  
  
Economy Secretary Ken Skates said: 


> “It is a considerable achievement that this small area of rural West Wales is a world leader in what is an extremely specialised, highly competitive and highly valued field. It once again illustrates the breadth of expertise we have in Wales within the life sciences sector.


> “MicroPharm is a key contributor to Wales’ expertise and I am delighted Welsh Government support will enable its  planned expansion to go ahead immediately. The investment will provide the additional facilities required to meet the growing global demand for its products. It will also enable the company to capitalise on opportunities to increase its product range and support its on\-going research to provide treatments for devastating diseases like Clostridium difficile Infection (CDI) and Ebola.


> “This very important expansion project will further embed a specialist pharmaceutical R\&D and manufacturing company in West Wales and provide opportunities for local people to access high quality jobs.”

Skills and Science Minister, Julie James added: 


> “Wales’ life sciences sector has gone from strength to strength over recent years and this latest announcement is welcome news for both the local community, wider Welsh economy and global   pharmaceutical marketplace.


> “As a relatively small country Wales punches well above its weight when it comes to scientific developments and world\-class research and this government remains committed to supporting innovative companies like MicroPharm to ensure this vitally important sector continues to grow in Wales.”

MicroPharm’s CEO, Ian Cameron, commented: 


> “We have outgrown our existing facilities in Newcastle Emlyn and the new manufacturing facility at Cilgerran will provide a platform for the long term growth of the company.  The Welsh Government has supported the growth of MicroPharm since its inception and we are grateful for the continued support”.

MicroPharm’s expertise lies in producing a range of immunotherapeutic products for clinical use – designed to treat acute, life threatening emergencies and required urgently either because no alternative exists or any alternatives are unsafe or ineffective.

In addition to anti\-venoms, MicroPharm is also working on developing a ricin antitoxin having been awarded a contract, valued at up to £7m, last year by the Defence Science and Technology Laboratory (Dstl) on behalf of the Ministry of Defence (MOD). It involves the production of ovine antibodies to ricin and their further processing and manufacture into a product suitable for human use. Ricin is a deadly poison with no antidote currently available.   
  
MicroPharm has a product pipeline of several new immunotherapeutic products for human and veterinary use ranging from early stage opportunities to clinical trials stage which are expected to come into the market from 2018\-2021\.